Angiotensin Receptor Blocker-Related Sprue-like Enteropathy: Review of Food and Drug Administration Adverse Event Reporting System
CONCLUSIONS AND RELEVANCE: Reports to FAERS for ARB-related SE are mostly related to olmesartan. There was a steep decline in reports of olmesartan-related SE following the lawsuit with potential of lawyer interference. There are reports of SE related to ARBs other than olmesartan, with increased physician awareness and the potential to discover a class effect with future studies.PMID:37559251 | DOI:10.1177/10600280231191834 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - August 10, 2023 Category: Drugs & Pharmacology Authors: Ryan Meader Sam Papasotiriou Hardeep Ahdi Hoang Dang Eli D Ehrenpreis Source Type: research
Angiotensin Receptor Blocker-Related Sprue-like Enteropathy: Review of Food and Drug Administration Adverse Event Reporting System
CONCLUSIONS AND RELEVANCE: Reports to FAERS for ARB-related SE are mostly related to olmesartan. There was a steep decline in reports of olmesartan-related SE following the lawsuit with potential of lawyer interference. There are reports of SE related to ARBs other than olmesartan, with increased physician awareness and the potential to discover a class effect with future studies.PMID:37559251 | DOI:10.1177/10600280231191834 (Source: The Annals of Pharmacotherapy)
Source: The Annals of Pharmacotherapy - August 10, 2023 Category: Drugs & Pharmacology Authors: Ryan Meader Sam Papasotiriou Hardeep Ahdi Hoang Dang Eli D Ehrenpreis Source Type: research
Change in Echocardiographic Parameters in Patients Receiving a Quadruple Ultra-Low-Dose Anti-Hypertensive Combination for Treatment of Hypertension
This group has previously demonstrated greater blood pressure (BP)-lowering effects using a quadruple ultra-low-dose combination of anti-hypertensives (irbesartan 37.5 mg, amlodipine 1.25 mg, indapamide 0.625 mg, bisoprolol 2.5 mg) ( “quadpill”) compared with standard monotherapy (irbesartan 150 mg). It sought to compare changes in echocardiographic parameters between the two groups after 12 months of treatment. (Source: Heart, Lung and Circulation)
Source: Heart, Lung and Circulation - July 1, 2023 Category: Cardiology Authors: P. Emerson, M. Schlaich, A. Rajwani, C. Chow, G. Hillis, L. Thomas Source Type: research
Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
CONCLUSION: In this nationwide cohort, fimasartan, compared with other ARBs, had comparable treatment effects for a composite of all-cause death, recurrent MI, hospitalization for heart failure, and stroke in patients with heart failure after MI.PMID:37365730 | DOI:10.3346/jkms.2023.38.e202 (Source: Journal of Korean Medical Science)
Source: Journal of Korean Medical Science - June 27, 2023 Category: Biomedical Science Authors: Jihoon Kim Danbee Kang Sung Eun Kim Hyejeong Park Taek Kyu Park Joo Myung Lee Jeong Hoon Yang Young Bin Song Jin-Ho Choi Seung-Hyuk Choi Hyeon-Cheol Gwon Eliseo Guallar Juhee Cho Joo-Yong Hahn Source Type: research
Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
CONCLUSION: In this nationwide cohort, fimasartan, compared with other ARBs, had comparable treatment effects for a composite of all-cause death, recurrent MI, hospitalization for heart failure, and stroke in patients with heart failure after MI.PMID:37365730 | DOI:10.3346/jkms.2023.38.e202 (Source: J Korean Med Sci)
Source: J Korean Med Sci - June 27, 2023 Category: General Medicine Authors: Jihoon Kim Danbee Kang Sung Eun Kim Hyejeong Park Taek Kyu Park Joo Myung Lee Jeong Hoon Yang Young Bin Song Jin-Ho Choi Seung-Hyuk Choi Hyeon-Cheol Gwon Eliseo Guallar Juhee Cho Joo-Yong Hahn Source Type: research
Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
CONCLUSION: In this nationwide cohort, fimasartan, compared with other ARBs, had comparable treatment effects for a composite of all-cause death, recurrent MI, hospitalization for heart failure, and stroke in patients with heart failure after MI.PMID:37365730 | PMC:PMC10293657 | DOI:10.3346/jkms.2023.38.e202 (Source: J Korean Med Sci)
Source: J Korean Med Sci - June 27, 2023 Category: General Medicine Authors: Jihoon Kim Danbee Kang Sung Eun Kim Hyejeong Park Taek Kyu Park Joo Myung Lee Jeong Hoon Yang Young Bin Song Jin-Ho Choi Seung-Hyuk Choi Hyeon-Cheol Gwon Eliseo Guallar Juhee Cho Joo-Yong Hahn Source Type: research
Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
CONCLUSION: In this nationwide cohort, fimasartan, compared with other ARBs, had comparable treatment effects for a composite of all-cause death, recurrent MI, hospitalization for heart failure, and stroke in patients with heart failure after MI.PMID:37365730 | PMC:PMC10293657 | DOI:10.3346/jkms.2023.38.e202 (Source: Journal of Korean Medical Science)
Source: Journal of Korean Medical Science - June 27, 2023 Category: Biomedical Science Authors: Jihoon Kim Danbee Kang Sung Eun Kim Hyejeong Park Taek Kyu Park Joo Myung Lee Jeong Hoon Yang Young Bin Song Jin-Ho Choi Seung-Hyuk Choi Hyeon-Cheol Gwon Eliseo Guallar Juhee Cho Joo-Yong Hahn Source Type: research
Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
CONCLUSION: In this nationwide cohort, fimasartan, compared with other ARBs, had comparable treatment effects for a composite of all-cause death, recurrent MI, hospitalization for heart failure, and stroke in patients with heart failure after MI.PMID:37365730 | PMC:PMC10293657 | DOI:10.3346/jkms.2023.38.e202 (Source: J Korean Med Sci)
Source: J Korean Med Sci - June 27, 2023 Category: General Medicine Authors: Jihoon Kim Danbee Kang Sung Eun Kim Hyejeong Park Taek Kyu Park Joo Myung Lee Jeong Hoon Yang Young Bin Song Jin-Ho Choi Seung-Hyuk Choi Hyeon-Cheol Gwon Eliseo Guallar Juhee Cho Joo-Yong Hahn Source Type: research
Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
CONCLUSION: In this nationwide cohort, fimasartan, compared with other ARBs, had comparable treatment effects for a composite of all-cause death, recurrent MI, hospitalization for heart failure, and stroke in patients with heart failure after MI.PMID:37365730 | PMC:PMC10293657 | DOI:10.3346/jkms.2023.38.e202 (Source: Journal of Korean Medical Science)
Source: Journal of Korean Medical Science - June 27, 2023 Category: Biomedical Science Authors: Jihoon Kim Danbee Kang Sung Eun Kim Hyejeong Park Taek Kyu Park Joo Myung Lee Jeong Hoon Yang Young Bin Song Jin-Ho Choi Seung-Hyuk Choi Hyeon-Cheol Gwon Eliseo Guallar Juhee Cho Joo-Yong Hahn Source Type: research
Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
CONCLUSION: In this nationwide cohort, fimasartan, compared with other ARBs, had comparable treatment effects for a composite of all-cause death, recurrent MI, hospitalization for heart failure, and stroke in patients with heart failure after MI.PMID:37365730 | PMC:PMC10293657 | DOI:10.3346/jkms.2023.38.e202 (Source: J Korean Med Sci)
Source: J Korean Med Sci - June 27, 2023 Category: General Medicine Authors: Jihoon Kim Danbee Kang Sung Eun Kim Hyejeong Park Taek Kyu Park Joo Myung Lee Jeong Hoon Yang Young Bin Song Jin-Ho Choi Seung-Hyuk Choi Hyeon-Cheol Gwon Eliseo Guallar Juhee Cho Joo-Yong Hahn Source Type: research
Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
CONCLUSION: In this nationwide cohort, fimasartan, compared with other ARBs, had comparable treatment effects for a composite of all-cause death, recurrent MI, hospitalization for heart failure, and stroke in patients with heart failure after MI.PMID:37365730 | PMC:PMC10293657 | DOI:10.3346/jkms.2023.38.e202 (Source: Journal of Korean Medical Science)
Source: Journal of Korean Medical Science - June 27, 2023 Category: Biomedical Science Authors: Jihoon Kim Danbee Kang Sung Eun Kim Hyejeong Park Taek Kyu Park Joo Myung Lee Jeong Hoon Yang Young Bin Song Jin-Ho Choi Seung-Hyuk Choi Hyeon-Cheol Gwon Eliseo Guallar Juhee Cho Joo-Yong Hahn Source Type: research
Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
CONCLUSION: In this nationwide cohort, fimasartan, compared with other ARBs, had comparable treatment effects for a composite of all-cause death, recurrent MI, hospitalization for heart failure, and stroke in patients with heart failure after MI.PMID:37365730 | PMC:PMC10293657 | DOI:10.3346/jkms.2023.38.e202 (Source: J Korean Med Sci)
Source: J Korean Med Sci - June 27, 2023 Category: General Medicine Authors: Jihoon Kim Danbee Kang Sung Eun Kim Hyejeong Park Taek Kyu Park Joo Myung Lee Jeong Hoon Yang Young Bin Song Jin-Ho Choi Seung-Hyuk Choi Hyeon-Cheol Gwon Eliseo Guallar Juhee Cho Joo-Yong Hahn Source Type: research
Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
CONCLUSION: In this nationwide cohort, fimasartan, compared with other ARBs, had comparable treatment effects for a composite of all-cause death, recurrent MI, hospitalization for heart failure, and stroke in patients with heart failure after MI.PMID:37365730 | PMC:PMC10293657 | DOI:10.3346/jkms.2023.38.e202 (Source: Journal of Korean Medical Science)
Source: Journal of Korean Medical Science - June 27, 2023 Category: Biomedical Science Authors: Jihoon Kim Danbee Kang Sung Eun Kim Hyejeong Park Taek Kyu Park Joo Myung Lee Jeong Hoon Yang Young Bin Song Jin-Ho Choi Seung-Hyuk Choi Hyeon-Cheol Gwon Eliseo Guallar Juhee Cho Joo-Yong Hahn Source Type: research
Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
CONCLUSION: In this nationwide cohort, fimasartan, compared with other ARBs, had comparable treatment effects for a composite of all-cause death, recurrent MI, hospitalization for heart failure, and stroke in patients with heart failure after MI.PMID:37365730 | PMC:PMC10293657 | DOI:10.3346/jkms.2023.38.e202 (Source: J Korean Med Sci)
Source: J Korean Med Sci - June 27, 2023 Category: General Medicine Authors: Jihoon Kim Danbee Kang Sung Eun Kim Hyejeong Park Taek Kyu Park Joo Myung Lee Jeong Hoon Yang Young Bin Song Jin-Ho Choi Seung-Hyuk Choi Hyeon-Cheol Gwon Eliseo Guallar Juhee Cho Joo-Yong Hahn Source Type: research
Comparison Between Fimasartan Versus Other Angiotensin Receptor Blockers in Patients With Heart Failure After Acute Myocardial Infarction
CONCLUSION: In this nationwide cohort, fimasartan, compared with other ARBs, had comparable treatment effects for a composite of all-cause death, recurrent MI, hospitalization for heart failure, and stroke in patients with heart failure after MI.PMID:37365730 | DOI:10.3346/jkms.2023.38.e202 (Source: Journal of Korean Medical Science)
Source: Journal of Korean Medical Science - June 27, 2023 Category: Biomedical Science Authors: Jihoon Kim Danbee Kang Sung Eun Kim Hyejeong Park Taek Kyu Park Joo Myung Lee Jeong Hoon Yang Young Bin Song Jin-Ho Choi Seung-Hyuk Choi Hyeon-Cheol Gwon Eliseo Guallar Juhee Cho Joo-Yong Hahn Source Type: research
